Activity of cabazitaxel/gemcitabine plus pembrolizumab in heavily pretreated urothelial carcinoma

Video

Vignesh Packiam, MD, urologist, assistant professor of Urology, University of Iowa Hospitals and Clinics, discusses the retrospective analysis, “Sequential endoluminal cabazitaxel and gemcitabine with pembrolizumab for docetaxel-unresponsive non-muscle invasive urothelial carcinoma of the upper and lower urinary tracts,” which he presented at the 2022 AUA Annual Meeting (abstract PD26-07).

Related Videos
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Illustration of human urinary bladder | Image Credit:  © magicmine - stock.adobe.com
Sandip M. Prasad, MD, MPhil, answers a question during a Zoom video interview
3d rendered illustration - bladder cancer | © SciePro - stock.adobe.com
Sandip M. Prasad, MD, MPhil, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.